142 related articles for article (PubMed ID: 23244184)
41. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E; Rolfo C; Viñal D; López I; Fusco JP; Santisteban M; Martin P; Zubiri L; Echeveste JI; Gil-Bazo I
J Transl Med; 2015 Aug; 13():257. PubMed ID: 26248464
[TBL] [Abstract][Full Text] [Related]
42. Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.
Lococo F; Paci M; Rapicetta C; Rossi T; Sancisi V; Braglia L; Cavuto S; Bisagni A; Bongarzone I; Noonan DM; Albini A; Maramotti S
Int J Mol Sci; 2015 Aug; 16(8):19612-30. PubMed ID: 26295387
[TBL] [Abstract][Full Text] [Related]
43. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.
Ramlau R; Cufer T; Berzinec P; Dziadziuszko R; Olszewski W; Popper H; Bajcic P; Dusšk L; Zbozinkova Z; Pirker R;
J Thorac Oncol; 2015 Sep; 10(9):1370-1374. PubMed ID: 26291014
[TBL] [Abstract][Full Text] [Related]
44. A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients.
Pamungkas AD; Medriano CA; Sim E; Lee S; Park YH
Mol Med Rep; 2017 Jun; 15(6):4155-4161. PubMed ID: 28487968
[TBL] [Abstract][Full Text] [Related]
45. A rapid MZI-IDA sensor system for EGFR mutation testing in non-small cell lung cancer (NSCLC).
Liu Q; Lim SY; Soo RA; Park MK; Shin Y
Biosens Bioelectron; 2015 Dec; 74():865-71. PubMed ID: 26233643
[TBL] [Abstract][Full Text] [Related]
46. Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.
Zhou F; Zhou CC
Chin J Cancer; 2015 Jul; 34(7):310-9. PubMed ID: 26187152
[TBL] [Abstract][Full Text] [Related]
47. [Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a "golden standard" in diagnostics?].
Skroński M; Szpechciński A; Chorostowska-Wynimko J
Pneumonol Alergol Pol; 2014; 82(3):311-22. PubMed ID: 24793156
[TBL] [Abstract][Full Text] [Related]
48. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Oser MG; Niederst MJ; Sequist LV; Engelman JA
Lancet Oncol; 2015 Apr; 16(4):e165-72. PubMed ID: 25846096
[TBL] [Abstract][Full Text] [Related]
49. The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases.
Bouhlel L; Hofman V; Maschi C; Ilié M; Allégra M; Marquette CH; Audigier-Valette C; Thariat J; Hofman P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1087-1092. PubMed ID: 29069959
[TBL] [Abstract][Full Text] [Related]
50. Could molecular pathology testing in lung cancer be more cost-effective?
Walsh K; Kheng YC; Oniscu A; Harrison DJ; Wallace WA
J Clin Pathol; 2016 Oct; 69(10):938-41. PubMed ID: 27387984
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathologic Features of Advanced Squamous NSCLC.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn P; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Stinchcombe TE; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Sep; 11(9):1411-22. PubMed ID: 27296106
[TBL] [Abstract][Full Text] [Related]
52. [Current morphological diagnosis of malignant lung tumors].
Junker K
Pathologe; 2006 Mar; 27(2):90-8. PubMed ID: 16435095
[TBL] [Abstract][Full Text] [Related]
53. [EFR-like peptides and their receptors as prognostic factors for the survival of patients with non-small-cell lung cancer].
Kostyleva OI; Gerstein ES; Dykhno AIu; Vasil'ev AV; Polotskiĭ BE; Kushlinskiĭ NE
Vopr Onkol; 1999; 45(6):617-22. PubMed ID: 10703508
[TBL] [Abstract][Full Text] [Related]
54. Occam's Razor and Hickam's Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC.
Conduit C; Hardikar A; Prasad R; Nott L
J Thorac Oncol; 2016 Nov; 11(11):e131-e133. PubMed ID: 27449806
[No Abstract] [Full Text] [Related]
55. Guidelines for multimodality radiological staging of lung cancer.
Loutfi S; Khankan A; Al Ghanim S
J Infect Public Health; 2012 Dec; 5 Suppl 1():S14-21. PubMed ID: 23244181
[TBL] [Abstract][Full Text] [Related]
56. Treatment choice in EGFR-mutant non-small-cell lung cancer.
Brueckl WM
Lancet Oncol; 2017 Nov; 18(11):1425-1426. PubMed ID: 28958503
[No Abstract] [Full Text] [Related]
57. Should we continue to use the term non-small-cell lung cancer?
Gazdar AF
Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii225-9. PubMed ID: 20943619
[TBL] [Abstract][Full Text] [Related]
58. [Clinical Evaluation of A New Pathological Classification for
Non-small Cell Lung Cancer Based on Histogenesis of Bronchial Tree].
Wang N; Jiang N; Yang X; Fang L; Sun Q
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):530-535. PubMed ID: 30037373
[TBL] [Abstract][Full Text] [Related]
59. EGFR mutation testing in cytology smears of advanced non-small cell lung carcinomas: Practical applications in low-resource laboratories.
Singh V; Nambirajan A; Malik PS; Kaur K; Mohan A; Jain D
Cytopathology; 2021 Mar; 32(2):287-289. PubMed ID: 33211362
[No Abstract] [Full Text] [Related]
60. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.
Dietel M; Bubendorf L; Dingemans AM; Dooms C; Elmberger G; García RC; Kerr KM; Lim E; López-Ríos F; Thunnissen E; Van Schil PE; von Laffert M
Thorax; 2016 Feb; 71(2):177-84. PubMed ID: 26530085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
